Globus Medical reaffirms FY25 stand-alone EPS $3.40-$3.50, consensus $3.47
On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...
Jefferies maintains Buy on Globus Medical, target at $105
Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...
Zacks.com on MSN7h
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
FY2024 EPS Estimates for Globus Medical Reduced by Analyst
Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...
American Association of Individual Investors7d
Which Is a Better Investment, Globus Medical, Inc. or Smith & Nephew plc Stock?
Learn more about whether Globus Medical, Inc. or Smith & Nephew plc is a better investment based on AAII's A+ Investor grades ...
Nevro price target raised to $5.85 from $5 at Baird
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...